260 related articles for article (PubMed ID: 36497316)
1. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Wu YL; Fulgenzi CAM; D'Alessio A; Cheon J; Nishida N; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ; Ang C
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497316
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
Wang JH; Chen YY; Kee KM; Wang CC; Tsai MC; Kuo YH; Hung CH; Li WF; Lai HL; Chen YH
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053508
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
Zhang L; Yan ZP; Hou ZH; Huang P; Yang MJ; Zhang S; Zhang S; Zhang SH; Zhu XL; Ni CF; Li Q
Front Mol Biosci; 2021; 8():624366. PubMed ID: 34124139
[No Abstract] [Full Text] [Related]
4. [Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma].
Kaneko Y; Kaneshiro M; Watanabe H
Nihon Shokakibyo Gakkai Zasshi; 2023; 120(10):837-844. PubMed ID: 37821373
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.
Kutlu Y; Aydin SG; Bilici A; Oven BB; Olmez OF; Acikgoz O; Hamdard J
Medicine (Baltimore); 2023 Apr; 102(15):e33432. PubMed ID: 37058061
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
[TBL] [Abstract][Full Text] [Related]
8. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.
Muhammed A; Fulgenzi CAM; Dharmapuri S; Pinter M; Balcar L; Scheiner B; Marron TU; Jun T; Saeed A; Hildebrand H; Muzaffar M; Navaid M; Naqash AR; Gampa A; Ozbek U; Lin JY; Perone Y; Vincenzi B; Silletta M; Pillai A; Wang Y; Khan U; Huang YH; Bettinger D; Abugabal YI; Kaseb A; Pressiani T; Personeni N; Rimassa L; Nishida N; Di Tommaso L; Kudo M; Vogel A; Mauri FA; Cortellini A; Sharma R; D'Alessio A; Ang C; Pinato DJ
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008350
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment.
Chon YE; Cheon J; Kim H; Kang B; Ha Y; Kim DY; Hwang SG; Chon HJ; Kim BK
Cancer Med; 2023 Feb; 12(3):2731-2738. PubMed ID: 35997637
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Ochi H; Kurosaki M; Joko K; Mashiba T; Tamaki N; Tsuchiya K; Marusawa H; Tada T; Nakamura S; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kusakabe A; Furuta K; Kobashi H; Arai H; Nonogi M; Tamada T; Hasebe C; Izumi N
Hepatol Res; 2023 Jan; 53(1):61-71. PubMed ID: 36070216
[TBL] [Abstract][Full Text] [Related]
12. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
Park Y; Chang AR
Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy.
Xia WY; Zhu XR; Feng W; Liu J; Wang JM; Lv CX; Zhang Q; Yu W; Cai XW; Fu XL
Transl Lung Cancer Res; 2020 Oct; 9(5):1996-2007. PubMed ID: 33209619
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
[TBL] [Abstract][Full Text] [Related]
16. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study.
Guo L; Ren H; Pu L; Zhu X; Liu Y; Ma X
Cancer Manag Res; 2020; 12():7173-7188. PubMed ID: 33061563
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
Leng J; Wu F; Zhang L
Front Oncol; 2022; 12():734948. PubMed ID: 35651788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
